Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00758199 · ClinicalTrials.gov registry record · Phase 4
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
A Phase 4 study of Cataracts, sponsored by Bp Consulting.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT00758199 is a Phase 4 study of Cataracts that has completed, run by Bp Consulting. The registered enrollment target is 49 participants, below the 92-participant average among 8 other Cataracts trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00758199, a Phase 4 study of Cataracts, has completed, sponsored by Bp Consulting.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to determine if an extension of bromfenac BID monotherapy is effective in the decreasing retinal thickening post cataract IOL placement surgery. No studies exist on how long to treat with an NSAID post cataract IOL placement surgery. Currently, NSAID therapy post IOL placement surgery is in conjunction with steroid treatment, lasting approximately 3 weeks. This study is designed to examine if there is benefit to extending NSAID monotherapy in regards to macular thickening and the incidence of CME.
Conditions Studied
Interventions
- DRUG Bromfenac
- DRUG Prednisolone Acetate
- DRUG Moxifloxacin hydrochloride
Study Locations (1)
California
- Altos Eye Physicians - Los Altos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00758199
The ClinicalTrials.gov registry entry for NCT00758199 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 8 other Cataracts trials with a reported enrollment target (47% lower). The listed sponsor is Bp Consulting, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataracts appearing as the primary indexed condition, and to 3 interventions - of which Bromfenac is the first listed.
NCT00758199 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00758199 about?
NCT00758199 is a clinical study titled "Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery". The objective of this study is to determine if an extension of bromfenac BID monotherapy is effective in the decreasing retinal thickening post cataract IOL placement surgery. No studies exist on how long to treat with an NSAID post cataract IOL placement surgery. Currently, NSAID therapy post IOL p...
What is the current status of trial NCT00758199?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2008-07. Estimated completion is 2010-01.
What conditions does trial NCT00758199 study?
This clinical trial studies the following conditions: Cataracts.
What interventions are being tested in trial NCT00758199?
The interventions under investigation include: Bromfenac (DRUG), Prednisolone Acetate (DRUG), Moxifloxacin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00758199?
This trial is sponsored by Bp Consulting, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00758199 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataracts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
COMPLETED · Phase 4
-
Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery
COMPLETED · Phase 4
-
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
COMPLETED · Phase 4
-
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.